Analgesic Solutions to Present Posters at Five Conferences in 2018
Analgesic Solutions will present proprietary tools and research posters at five conferences in 2018. We invite you to meet our team presenting the following research posters.
If you would like to schedule a meeting at any of the conferences or would like to learn more about the information being presenting, please contact Tony May at firstname.lastname@example.org or 781-444-9605 x120.
- American Academy of Pain (Vancouver, Canada):
“Assessment of a Systematic Framework to Determine the Equianalgesic Conversion Ratio Between Opioids: Determining the Conversion Ratio Between Tapentadol and Morphine”
- College of Problems of Drug Dependence (San Diego, CA):
“Nektar: Phase 3, Double-Blind, Placebo Controlled Study to Assess the Efficacy, Safety, and Tolerability of NKTR-181 in Opioid-Naïve Subjects with Moderate to Severe Chronic Low Back Pain”
“Assessment of Drug-Abuse Related Events with MADDERS in SUMMIT-07: A Phase-3 Study of NKTR-181 in Patients with Moderate to Severe Chronic Low-Back Pain”
- DIA 2018 Global Annual Meeting (Boston, MA):
“MADDERS: A Systematic Approach to Meeting Regulatory Requirements for Evaluating Abuse-Related Events in Clinical Trials”
“Placebo Response Reduction Training in Chronic Low Back Pain: Comparison to Other Published Studies on Chronic Low Back Pain”
- IASP World Congress on Pain (Boston, MA):
- Pain and Migraine Therapeutics Summit (San Francisco, CA):
Analgesic Solutions, LLC, founded in 2006, is a privately held company focused on increasing assay sensitivity in the conduct of pain clinical trials through consulting, innovative tools and technology, and training. Our team, with Nathaniel Katz M.D., M.S., serving as our foremost expert, helps clients develop and commercialize better treatments for pain. With hundreds of projects completed and ongoing collaborations with regulatory authorities, Analgesic Solutions is the expert at identifying and mitigating the random and systematic errors that lead to negative clinical trials.